ChitoCare Medical Wound Healing Gel PMCF Study on Healing of Chronic Wounds
Launched by PRIMEX EHF · Oct 4, 2022
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
The purpose of this PMCF study is to evaluate the safety and efficacy of ChitoCare medical Wound Healing Gel for the healing of chronic wounds. The study will enroll patients with diabetic foot ulcer, venous ulcer or pressure ulcer. Patients will be randomly assigned to an active or control group. The active group will apply the gel to the wound, in addition to the standard of care, while the control group will receive only standard care. The study will last from 3 to 18 months for an individual patient (15-month recruitment period and 3 months of follow-up after the last patient is enrolle...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Written informed consent must be given
- • 2. Patient ≥ 18 years old
- 3. Presence of chronic wound (Wagner grade I and II diabetic foot ulcer, venous leg ulcer or pressure ulcer) that meets the following criteria:
- • Size of the wound ≥ 0.5 cm2
- • Wound is not infected at the time of randomization
- • Wound is present for at least 4 weeks
- • 4. Able to understand and comply with the requirements of the study
- Exclusion Criteria:
- • 1. Patients with serious concomitant disease (cancer, heart failure (NYHA class IV), severe anaemia (Hb\<100 g/L), neoplasia)
- • 2. Any significant condition that may preclude the participant from the study (e.g. severe depression or psychiatric illness)
- • 3. Patients that will require surgical procedure to treat their ischemic condition on the limb where the wound is present as assessed by the investigator
- • 4. Patients diagnosed with autoimmune connective tissue diseases
- • 5. Previous treatment under this clinical protocol
- • 6. Participation in another clinical trial
- • 7. Receiving or scheduled to receive a medication or treatment which, in the opinion of the investigator, was known to interfere with, or affect the rate and quality of wound healing
- • 8. Allergy to shellfish (for active study group)
- • 9. Medical condition likely to require systemic corticosteroids during the study period
- • 10. Pregnant and lactating women
About Primex Ehf
Primex ehf is a clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on enhancing patient outcomes, Primex ehf engages in the design and execution of rigorous clinical trials across various therapeutic areas. The organization adheres to the highest ethical standards and regulatory compliance, ensuring patient safety and data integrity throughout the research process. Leveraging a team of experienced professionals, Primex ehf collaborates with academic institutions, healthcare providers, and industry partners to bring cutting-edge therapies from concept to market, ultimately contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Celje, , Slovenia
Koper, , Slovenia
Maribor, , Slovenia
šmarje Pri Jelšah, , Slovenia
Zagreb, , Croatia
Zagreb, , Croatia
Zagreb, , Croatia
Poljčane, , Slovenia
žalec, , Slovenia
Patients applied
Trial Officials
Helene Liette Lauzon
Study Director
Primex ehf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials